-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Peritoneal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Peritoneal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Peritoneal Cancer Drug Details: TG-4050 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Darleukin in Melanoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Darleukin in Melanoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Darleukin in Melanoma Drug Details: Darleukin (L19-IL2) is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Fallopian Tube Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Fallopian Tube Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Fallopian Tube Cancer Drug Details: TG-4050 is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Spartalizumab in Esophageal Squamous Cell Carcinoma (ESCC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Spartalizumab in Esophageal Squamous Cell Carcinoma (ESCC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Spartalizumab in Esophageal Squamous Cell Carcinoma (ESCC) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TG-4050 in Head And Neck Cancer Squamous Cell Carcinoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - TG-4050 in Head And Neck Cancer Squamous Cell Carcinoma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. TG-4050 in Head And Neck Cancer Squamous...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ruxolitinib Phosphate in Laryngeal Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ruxolitinib Phosphate in Laryngeal Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ruxolitinib Phosphate in Laryngeal Cancer Drug Details: Ruxolitinib (INCB18424, Jakafi,...
-
Product Insights
Post-Polycythemia Vera Myelofibrosis (PPV-MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Polycythemia Vera Myelofibrosis (PPV-MF) - Drugs In Development, 2023’, provides an overview of the Post-Polycythemia Vera Myelofibrosis (PPV-MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Polycythemia Vera Myelofibrosis (PPV-MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) – Drugs In Development, 2023
Global Markets Direct’s, ‘Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) - Drugs In Development, 2023’, provides an overview of the Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...
-
Product Insights
Myelofibrosis – Drugs In Development, 2023
Global Markets Direct’s, ‘Myelofibrosis - Drugs In Development, 2023’, provides an overview of the Myelofibrosis pipeline landscape. The report provides comprehensive information on the therapeutics under development for Myelofibrosis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Icosabutate in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: Icosabutate (PRC-4016;...